Skip to main content

Surgical Wound Infection

3
Pipeline Programs
8
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
2
Amoxicillin/clavulanic acidPhase 4
cefuroximePhase 4
Innovation Pharmaceuticals
1 program
1
Amicidin-β topical solution - 15 mLPhase 1
Next Science
Next ScienceAustralia - Sydney
1 program
Next ScienceN/A1 trial
Active Trials
NCT04906642Terminated17Est. Sep 2023
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Prophylactic NPWTN/A1 trial
Active Trials
NCT03009110Terminated1,624Est. Nov 2019
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
SafeHaven Automated Hand Hygiene DeviceN/A1 trial
Active Trials
NCT04900298Recruiting40Est. Jun 2026
Pacific Science
Pacific ScienceCA - Torrance
1 program
SafeHaven Automated Hand Hygiene DeviceN/A
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
Amicidin-β topical solution - 15 mLPHASE_11 trial
Active Trials
NCT07379684Recruiting44Est. Feb 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Novo NordiskAmicidin-β topical solution - 15 mL
Oregon TherapeuticsSafeHaven Automated Hand Hygiene Device
Next ScienceNext Science
Human BioSciencesProphylactic NPWT

Clinical Trials (4)

Total enrollment: 1,725 patients across 4 trials

NCT07379684Novo NordiskAmicidin-β topical solution - 15 mL

A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections

Start: Apr 2026Est. completion: Feb 202744 patients
Phase 1Recruiting
NCT04900298Oregon TherapeuticsSafeHaven Automated Hand Hygiene Device

Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System

Start: Jan 2022Est. completion: Jun 202640 patients
N/ARecruiting
NCT04906642Next ScienceNext Science

Clinical Assessment of Next Science Solution on Gustilo and Anderson Type II and IIIA or IIIB Tibial Fractures

Start: May 2021Est. completion: Sep 202317 patients
N/ATerminated
NCT03009110Human BioSciencesProphylactic NPWT

Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial

Start: Feb 2017Est. completion: Nov 20191,624 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 1,725 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.